AsPC-1 Transfection Reagent (Pancreatic Beta Cells)


Kit Size VolumePricePay with CC, PO, or PaypalAdd to Cart
0.5 ml (Catalog #1709)$368.00
1.5 ml CRISPR (Catalog #2109)$712.00
1.5 ml (Catalog #1710)$712.00
8.0 ml (Catalog #7023)$1,836.00
SKU: ASPC1 Category:


Purchase Orders: Click “Add to Cart” button to order, then email PO to

Product Availability: In Stock.

Transfection Reagent for ASPC-1 Cells (Pancreatic Beta Cells, CRL-1682)

  • A nanoparticle-based liposome formulation
  • Transfection protocols provided for transfection of proteins, DNA, mRNA, siRNA, shRNA and microRNA
  • Transfection Enhancer reagent provided with the kit
  • Produce higher level of recombinant protein expression with minimal disruption of normal cell function
  • Generate physiologically relevant data you can trust
  • Effective for plasmid DNA/siRNA co-transfection
  • Easy-to-use transfection protocol with reproducible results
  • Low cytotoxicity
  • Download in vitro ASPC-1 transfection protocol: [PDF]
  • Download ASPC-1 CRISPR/Cas9 transfection protocol: [PDF]
  • Download PowerPoint presentation for ASPC-1 cells transfection kit: [PPT]
  • UPC/GTIN/EAN: 860002089730
  • Brand: ALTOGEN®, developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 70% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Product Description:

This transfection kit is specially designed for the AsPC-1 cell line, a human pancreatic adenocarcinoma cells. Transfection reagent supplemented by complex condenser and transfection enhancer ensures high efficiency in delivering cargo biomolecules into these cells.

Transfection Protocol and SDS:

Download Altogen Biosystems ASPC-1 Transfection Protocol: [PDF]

Download SDS: [PDF]

ASPC-1 Cell Line:

Pancreatic cancer is one of the most challenging cancers to diagnose, as there no specific and reliable screening tests on the market that can help detect the disease in early stages. According to the American Cancer Society, if caught in its early stages, the 5-year survival rate is 27%, but if cancer metastasizes then this number goes down to 11%. The AsPC-1 cell line comprising pancreatic beta cells and is an invaluable tool for pancreatic cancer research as well as commonly employed for studying human infections related to the pancreas. The AsPC-1 cell line was reestablished via nude mouse xenografts initiated with cells from the ascites of a 62-year-old Caucasian woman with metastatic pancreatic adenocarcinoma. The reestablished epithelial cells retained their original morphology. This tumor represents a new model for human pancreatic cancer. AsPC-1 cells are used in studies seeking possible treatments for pancreatic cancer, which has a five-year survival rate of less than one percent. For examples, research has shown that the plant alkaloid sanguinarine induced apoptosis of AsPC-1 cells. In another study, immunoprecipitation and ELISA using human pancreatic cancer cells revealed the presence of high levels of DcR3 protein in AsPC-1 cells. Reducing endogenous DcR3 levels increases FasL-induced apoptosis of human pancreatic cancer cells. Another intriguing study indicated that deuterium oxide (D2O), also called heavy water, induced apoptosis of AsPC-1, and is considered a possible future treatment against AsPC-1.

ASPC1 is a human pancreatic adenocarcinoma cell line that was originally isolated from a metastatic lesion in the liver of a patient with pancreatic cancer. This cell line is commonly used as a model system for studying pancreatic cancer and for evaluating potential therapies. ASPC1 cells are known for their ability to form tumors in vivo when injected into immunodeficient mice, and they are commonly used in preclinical studies to evaluate the efficacy of potential pancreatic cancer therapies. These cells have also been used to study the molecular mechanisms underlying pancreatic cancer development and progression. ASPC1 cells are commonly cultured as adherent monolayers and have been shown to express markers of pancreatic adenocarcinoma, such as CA19-9 and MUC1. They are also known to be resistant to certain chemotherapeutic agents, which makes them useful for studying drug resistance mechanisms and testing new therapeutic strategies. In addition to their use as a model system for studying pancreatic cancer, ASPC1 cells have been used to study a many biological processes, including cell signaling pathways, cell cycle, apoptosis, and autophagy. They have also been used to study the interactions between cancer cells and the immune system and to evaluate potential immunotherapies for pancreatic cancer.


PANK4 55229 37 1 2442807 2442807 Silent SNP A G
ACTRT2 140625 37 1 2938457 2938457 Silent SNP G A
UBE4B 10277 37 1 10177606 10177606 Missense_Mutation SNP A G
EXOSC10 5394 37 1 11142785 11142785 Missense_Mutation SNP C T
VPS13D 55187 37 1 12337606 12337606 Missense_Mutation SNP G A
ZNF593 51042 37 1 26496958 26496958 Missense_Mutation SNP G T
RLF 6018 37 1 40701798 40701798 Missense_Mutation SNP T C
DOCK7 85440 37 1 63096986 63096986 Missense_Mutation SNP T C



Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in the AsPC-1 cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=3).


Figure 2. Protein expression of Cyclophilin B in AsPC-1 cells. DNA plasmid expressing Cyclophilin B or siRNA targeting Cyclophilin B were transfected into AsPC-1 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):

  • Nature. 2008 454(7203):523-7. Innate immunity induced by composition-dependent RIG-I …Saito et al [PDF]
  • Am J Pathology. 2010 177(4):1870-80. Role of ocular complement factor H in a murine model … Lyzogubov et al [PDF]
  • Nature Biotechnology. 2011 29(4):341-5. Delivery of siRNA to the mouse brain by … Alvarez-Erviti et al [PDF]
  • Cancer Research. 2011 71(15):5144-53. Inhibition of miR-193a expression by… Iliopoulos et al [PDF]
  • RNA. 2010 16(11):2108-19. RNase L releases a small RNA from HCV RNA that refolds … Malathi et al [PDF]
  • Diabetologia. 2012 55(7):2069-79. The p47phox- and NADPH oxidase organiser 1 … Youn et al [PDF]
  • British Journal of Cancer. 2012 107(3):516-26. TIGAR induces p53-mediated cell-cycle … Madan et al [PDF]
  • Hypertension. 2014 63(2):353-61. Tissue transglutaminase contributes to … Liu et al [PDF]
  • Circulation Research. 2010 15;107(8). Kruppel-like factor-4 transcriptionally regulates … Cowan et al [PDF]
  • Hypertension. 2012 59(1):158-66. Role of uncoupled endothelial nitric oxide synthase … Gao et al [PDF]
  • Jounal of Biological Chemistry. 2012 287(4):2907. Chaperoning of mutant p53 protein … Gogna et al [PDF]
  • PLoS Pathogens. 2012 8(8) Uridine composition of the poly-U/UC tract of HCV RNA … Schnell et al [PDF]

Altogen Biosystems provides preoptimized transfection products for life science research applications. Transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits for animal research: Tissue-targeted reagents (delivery to liver, pancreas, and kidney tissues), and broad range in vivo delivery reagents (PEG-Liposome, Nanoparticle-based, Lipid-based, and Polymer-based kits). Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, RNA, and any other negatively charged molecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource. Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (90+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit

AsPC1 Transfection Reagent

Volume Options:

  • 0.5 ml (Catalog #1709)
  • 1.5 ml (Catalog #1710)
  • 1.5 ml CRISPR (Catalog #2109)
  • 8.0 ml (Catalog #7023)

Purchase Orders: Click “Add to Cart” button to order, then email PO to

Product Availability: In Stock.

Additional information

Weight 1 lbs
Dimensions 4 × 3 × 0.2 in
Kit Size (Volume)

0.5 ml (Catalog #1709), 1.5 ml (Catalog #1710), 1.5 ml CRISPR (Catalog #2109), 8.0 ml (Catalog #7023)